Trial Profile
Long-term follow-up study to monitor the growth and development of pediatric patients previously treated with everolimus in study CRAD001M2301
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 04 Mar 2024
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Astrocytoma; Tuberous sclerosis
- Focus Therapeutic Use
- Acronyms EXIST-LT
- Sponsors Novartis
- 29 Jan 2024 Status changed from active, no longer recruiting to completed.
- 19 Jan 2024 This trial has been completed in Belgium (Global end date: 18 Dec 2023).
- 03 Dec 2021 Planned primary completion date changed from 25 Sep 2026 to 8 Jun 2026.